All In Biotech

Drug Trial Radar · NCT06994845

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

31

Planned (sponsor's estimate)

Start

Nov 27, 2025

Primary completion

Jun 28, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A nephropathy (IgAN) pediatric patients aged 2 to \<18 years.

Conditions

  • Primary Immunoglobulin A Nephropathy (IgAN)

Interventions

  • iptacopanDrug

    Cohort 1 (12 to \< 18 years of age): Iptacopan 200 mg b.i.d.(twice daily) Cohort 2 (2 to \< 12 years old): Dosing tbd

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Log-transformed ratio to Baseline in UPCR (based on FMV)Time frame: Baseline, Week 38

Locations

20 sites in 8 countries. Site status is shown where the registry gives one.

  • Valley Childrens Hospital

    Madera, California · Recruiting

  • Childrens Hospital Colorado

    Aurora, Colorado · Recruiting

  • Univ of Florida Shands Division

    Gainesville, Florida · Recruiting

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Prim Childrens Hosp Inv Pharm

    Salt Lake City, Utah · Recruiting

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Novartis Investigative Site

    Brisbane, Queensland, Australia · Recruiting

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China · Recruiting

  • Novartis Investigative Site

    Hong Kong, Hong Kong · Recruiting

  • Novartis Investigative Site

    Beersheba, Israel · Recruiting

  • Novartis Investigative Site

    Haifa, Israel · Recruiting

  • Novartis Investigative Site

    Jerusalem, Israel · Recruiting

  • Novartis Investigative Site

    Petah Tikva, Israel · Recruiting

  • Novartis Investigative Site

    Toyoake, Aichi-ken, Japan · Recruiting

  • Novartis Investigative Site

    Kurume, Fukuoka, Japan · Recruiting

  • Novartis Investigative Site

    Ōtsu, Shiga, Japan · Recruiting

  • Novartis Investigative Site

    Fuchū, Tokyo, Japan · Recruiting

  • Novartis Investigative Site

    Riyadh, Saudi Arabia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.